Trending...
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella.
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft
- A Story of Loyalty and Loss: Boone Forever Reflects on the Dog That Changed One Man's Life
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
0 Comments
Latest on Wisconsin Eagle
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- New Book Reveals The Science Of Predictions
- Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- EFA Announces 2026 Editorial Rate Chart
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- Shoutout Joseph Neibich aka Nybyk
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- The Retirement Advantage, Inc. Expands Sales Force with Appointment of Brad Wehrfritz as Regio
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
- Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
- NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture